文献速递心力衰竭与心肌病心律失常血脂与心血管预防

左心室过度小梁化与扩张型心肌病预后

Left Ventricular Hypertrabeculation and Prognosis in Dilated Cardiomyopathy.
PubMed 文献 · Circulation · 2026-08-03

该多中心研究纳入1160例扩张型心肌病(DCM)患者,经心脏磁共振和基因检测评估左心室过度小梁化。中位随访5.1年,过度小梁化与栓塞事件、晚期心衰及恶性室性心律失常风险均无显著关联,不支持预防性抗凝。

要点

  • DCM中左心室过度小梁化常见(30.5%),但不增加栓塞风险。
  • 过度小梁化不增加室性心律失常或晚期心衰风险。
  • 不应因过度小梁化而改变DCM的临床管理或预防性抗凝。

核心结论

  • 左心室过度小梁化在DCM中常见,但与不良预后无关,不应据此改变临床管理。

研究设计与样本

  • 国际多中心回顾性研究,纳入1160例DCM患者,其中997例(86%)接受基因检测。

主要发现

  • 中位随访5.1年(IQR 2.8-7.4),栓塞事件37例(3.2%),晚期心衰62例(5.3%),恶性室性心律失常136例(11.7%)。
  • 过度小梁化与栓塞风险无关(HR 1.5,95%CI 0.75-3.00),在窦性心律且LVEF≤40%患者中亦无关(HR 1.89,95%CI 0.7-5.5)。
  • 房颤和LVEF降低与栓塞事件相关(均P<0.01)。
  • 过度小梁化与恶性室性心律失常或晚期心衰风险无关;基因型、LVEF和晚期钆增强是主要预测因素。
  • 过度小梁化患病率因基因型而异:运动肌节基因变异58%,TTN 38%,基因型阴性33%,细胞骨架/Z盘7%,核膜5%。

关键数值与推荐

  • 过度小梁化定义为分形分析(30.5%)或Petersen标准(29.7%)识别,两者一致性良好。

临床怎么用

  • DCM患者合并过度小梁化时,栓塞风险低,尤其LVEF降低但无房颤者,不支持预防性抗凝。
  • 临床管理应基于房颤、LVEF降低、基因型及晚期钆增强等明确危险因素,而非过度小梁化本身。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Left ventricular (LV) hypertrabeculation, formerly termed LV noncompaction, is a heterogeneous myocardial entity linked to adverse cardiovascular outcomes. This study evaluated embolic risk in patients with dilated cardiomyopathy (DCM) according to the presence of hypertrabeculation and examined its prevalence and prognostic relevance across DCM genotypes. METHODS: Clinical data from 1160 patients with DCM evaluated by cardiac magnetic resonance imaging and genetic testing (n=997 [86%]) were collected from 22 international centers. End points included embolic events, advanced heart failure events, and major ventricular arrhythmias. RESULTS: LV hypertrabeculation was identified in 354 patients (30.5%) by fractal analysis and in 343 (29.7%) according to Petersen criteria, with good concordance. After a median follow-up of 5.1 years (interquartile range, 2.8-7.4), embolic events occurred in 37 patients (3.2%), advanced heart failure in 62 (5.3%), and major ventricular arrhythmias in 136 (11.7%). Hypertrabeculation was not associated with increased embolic risk (hazard ratio, 1.5 [95% CI, 0.75-3.00]), even among patients in sinus rhythm with LV ejection fraction ≤40% (hazard ratio, 1.89 [95% CI, 0.7-5.5]). In contrast, atrial fibrillation and reduced LV ejection fraction were associated with embolic events (both P<0.01). LV hypertrabeculation was not associated with an increased risk of major ventricular arrhythmias or advanced heart failure; genotype, LV ejection fraction, and late gadolinium enhancement emerged as the main predictors of adverse outcomes. The prevalence of LV hypertrabeculation varied across genotypes, with the highest prevalence observed in patients with sequence variants in motor sarcomeric genes (58%), TTN (38%), and genotype-negative status (33%), and the lowest prevalence observed among those with variants in cytoskeletal/Z-disk (7%) and nuclear envelope (5%) genes. Hypertrabeculation was not associated with adverse outcomes within any genotype. CONCLUSIONS: Although LV hypertrabeculation is common in DCM, it is not associated with worse outcomes and should not prompt differential clinical management. The embolic risk in patients with DCM and hypertrabeculation is low, including in those with reduced LV ejection fraction without atrial fibrillation, and does not support prophylactic anticoagulation in these patients.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Mora-Ayestarán N, Ramos-Lopez N, Ochoa JP, et al. Left Ventricular Hypertrabeculation and Prognosis in Dilated Cardiomyopathy. Circulation. 2026. PMID: 42546101. doi:10.1161/CIRCULATIONAHA.125.078536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。